Majority of Fed Officials Leaning Against July Interest-Rate Cut
(Bloomberg) -- A flurry of Federal Reserve officials this week made clear they'll need a few more months to gain confidence that tariff-driven price hikes won't raise inflation in a persistent way.
US Renters Face Storm of Rising Costs
US State Budget Wounds Intensify From Trump, DOGE Policy Shifts
Mapping the Architectural History of New York's Chinatown
Squeezed by Crowds, the Roads of Central Park Are Being Reimagined
Commuters Are Caught in Johannesburg's Taxi Feuds as Transit Lags
Fed Governors Christopher Waller and Michelle Bowman captured attention in the past week when they signaled they'd be open to lowering rates as soon as the Fed's July 29-30 meeting if inflation remains contained.
Since then, however, nearly a dozen policymakers — including Chair Jerome Powell, New York Fed President John Williams and San Francisco Fed chief Mary Daly — have dumped cold water on that idea.
In an interview Thursday on Bloomberg Surveillance, Daly acknowledged she's seeing increasing evidence that tariffs may not lead to a large or sustained inflation surge. But that merely made her open to a rate cut 'in the fall.'
'My modal outlook has been for some time that we would begin to be able to adjust the rates in the fall, and I haven't really changed that view,' Daly said.
Prices have cooled more than forecast this year, with the Fed's preferred gauge rising 2.1% in April, just above the central bank's 2% target.
Data released earlier Thursday also showed continuing claims for unemployment benefits jumped to their highest level since November 2021, extending a sharp increase over the past six weeks and signaling more people are staying out of work for longer. At the same time, initial jobless claims fell in the week ended June 21.
Daly said that while the labor market is slowing, she's not seeing warnings signs that its weakening.
She repeated her view that monetary policy is currently in a 'good place.'
Other Officials
Speaking separately Thursday, three other Fed officials signaled they aren't ready to support a cut at the Fed's next meeting.
'We're only going to have really one more month of data before the July meeting,' Boston Fed President Susan Collins said Thursday in an interview with Bloomberg New. 'I expect to want to see more information than that.'
Collins said her baseline outlook is to resume cutting later in the year.
'That could mean one rate cut, it's possible it means more than that, but I think the data will really need to tell us,' she said. 'I am not seeing an urgency.'
Richmond Fed President Tom Barkin, in remarks to the New York Association for Business Economics, said he expects tariffs will put upward pressure on prices. With so much remaining uncertain, he added, the central bank should wait for more clarity before adjusting rates.
'There is little upside in heading too quickly in any one direction,' Barkin said. 'Given the strength in today's economy, we have time to track developments patiently and allow the visibility to improve.'
Chicago Fed President Austan Goolsbee said the central bank could resume rate cuts if inflation is clearly trending toward policymakers' 2% goal and uncertainty over the economic outlook recedes.
'I'm optimistic that we've been getting good readings and maybe the impact of tariffs will be held just in their lane, but we want to be sure,' he said.
Powell
In testimony before a congressional panel on Tuesday, Powell said the Fed would probably be cutting rates by now, based on declining inflation, if not for the uncertain outlook for future prices because of tariffs. In the meantime, there was no need to rush into any rate changes.
'The effects of tariffs will depend, among other things, on their ultimate level,' Powell said. 'For the time being, we are well positioned to wait to learn more about the likely course of the economy before considering any adjustments to our policy stance.'
--With assistance from María Paula Mijares Torres, Amara Omeokwe, Maria Eloisa Capurro, Lisa Abramowicz and Jonathan Ferro.
(Updates with Collins comments from 11th paragraph.)
How to Steal a House
Inside Gap's Last-Ditch, Tariff-Addled Turnaround Push
Apple Test-Drives Big-Screen Movie Strategy With F1
America's Top Consumer-Sentiment Economist Is Worried
Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags
©2025 Bloomberg L.P.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire
Scott Galloway had a plan: sell his company, take $25 million, raise another $250 million, and become a billionaire. But then he stopped to think about it. 'Why would I want back on this hamster wheel of stress?' he asked on a recent episode of his podcast, 'Office Hours.' Galloway, a business professor, entrepreneur and investor, said he realized the pursuit of more wealth would just cost him time, peace of mind and family moments. 'I've been doing nothing but working for a quarter century,' he said. After hitting his personal financial target, he made a different choice: spend on what brings joy, pay people well, and give the rest away. 'I hit my number eight years ago,' he said. 'And I decided there's just no reason why I would ever need to be a billionaire.' Don't Miss: Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can invest with $1,000 at just $0.30/share. Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. 'Every year I look at my number,' he explained. 'Anything above that number, I do one of two things: I either spend it or I give it away.' He added, 'It feels amazing to spend money and to give it away.' He owns a plane and refuses to let money prevent him from enjoying life. When friends can't afford to join, he covers the cost himself, saying it gives him satisfaction. His shift in mindset mirrors that of Andrew Wilkinson, a Canadian entrepreneur who told his own story in the 2024 book, 'Never Enough.' Wilkinson became a billionaire after building the tech conglomerate Tiny, but eventually saw the limits of wealth. After nearly partnering with legendary investor Charlie Munger, Wilkinson said he turned it down. The thought of chasing another level of wealth no longer appealed to him. Both Wilkinson and Galloway reached a similar conclusion. Once you have enough, more doesn't necessarily improve your life. In fact, it can increase stress. Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — Become an Investor in This $41.3M Clean Energy Brand Today Galloway recalls the fear he felt in 2008 when his first son was born during the financial crisis. 'All I felt was shame and fear,' he said. 'I thought, I've failed this kid. I don't have enough money.' That fear stayed with him until he reached financial security. 'Happiness is not only a function of the things you have,' he said. 'It's a function of the things that you don't have—specifically, an absence from stress.' Galloway also wants to normalize open conversations about money. 'This zeitgeist that you're not supposed to talk about money is nothing but an effort by rich people to keep the poor and middle class down,' he said. He encourages people to share information about salaries, taxes and financial tools to help each other get ahead. 'Talking about it a lot gives you ideas and opportunities and can be quite cathartic,' he said. These days, Galloway says he's off the hamster wheel for good. He spends on joy, gives generously and says he finally feels free. Read Next: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Are you rich? Here's what Americans think you need to be considered 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
31 minutes ago
- Yahoo
Jeff Andrews: 'Never seen culture better than it is right now' at Hendrick Motorsports
Jeff Andrews: 'Never seen culture better than it is right now' at Hendrick Motorsports Jeff Andrews, president of Hendrick Motorsports, gives his insight into the current culture of Hendrick Motorsports after Chase Elliott's victory.
Yahoo
43 minutes ago
- Yahoo
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
The company's CFO resigned from his position. One law firm wasn't shy about reminding investors of the departure. 10 stocks we like better than Iovance Biotherapeutics › There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week was originally published by The Motley Fool Sign in to access your portfolio